CutisPharma Revenue and Competitors
Estimated Revenue & Valuation
- CutisPharma's estimated annual revenue is currently $118.8M per year.
- CutisPharma received $Undisclosed in venture funding in January 2015.
- CutisPharma's estimated revenue per employee is $281,400
- CutisPharma's total funding is $20M.
Employee Data
- CutisPharma has 422 Employees.
- CutisPharma grew their employee count by 17% last year.
CutisPharma's People
| Name | Title | Email/Phone |
|---|
CutisPharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is CutisPharma?
CutisPharma, Inc., based in Wilmington, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending.
keywords:N/A
$20M
Total Funding
422
Number of Employees
$118.8M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CutisPharma News
Massachusetts pharmaceutical company CutisPharma Inc. has acquired Silvergate Pharmaceuticals Inc., creating a new, unified company ...
WOBURN, Mass., March 26, 2019 /PRNewswire/ -- CutisPharma, Inc. announced today the opening of its new corporate headquarters in ...
WILMINGTON, Mass., Jan. 15, 2019 /PRNewswire/ -- CutisPharma, Inc. announced today the appointments of Mike Radice as Chief ...
CutisPharma, a Wilmington, Mass.-based developer of “value-added kits” for the compounding pharmacy market, raised an undisclosed amount of venture capital and debt funding. Ampersand Capital Partners made the investment while Silicon Valley Bank provided a senior credit facility from. In conju ...
Other Companies in Wilmington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $106.9M | 426 | 25% | N/A |
#2 | $53.3M | 426 | 3% | N/A |
#3 | $78.5M | 433 | -13% | N/A |
#4 | $89.4M | 433 | 7% | N/A |
#5 | $148.5M | 440 | N/A | N/A |
CutisPharma Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-01-05 | $20.0M | Undisclosed | Article | |
| 2015-01-07 | $Undisclosed | Undisclosed | Ampersand Capital Partners | Article |